A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects
Authors
Qin Yang (ORCID: https://orcid.org/0000-0003-3566-8898)
Huiling Qin
Yan Jiang (ORCID: https://orcid.org/0000-0002-2745-4323)
Juan Wu (ORCID: https://orcid.org/0000-0002-2580-9936)
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects
Qin Yang, Huiling Qin, Yan Jiang, Juan Wu et al.
Journal
Expert Opinion on Biological Therapy
Topics
Biosimilars and Bioanalytical Methods
article
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects
Qin Yang, Huiling Qin, Yan Jiang, Juan Wu, Zhijie Liu, Qingfeng Dong, Yu Liu, Wei Hu, Qin Zhang, Qian Zhang
article en
Abstract
No abstract available for this paper.
Publication Tag
Expert Opinion on Biological TherapyVol. 25(10)
Institutions
Anhui Medical University (CN), Biobyte Solutions (Germany) (DE), Guangzhou Regenerative Medicine and Health Guangdong Laboratory (CN), Second Affiliated Hospital of Anhui Medical University (CN)